Halo Pharma Announces Investment and Formal Collaboration with Altus
News May 16, 2013
Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems.
Halo is focused on satisfying the pharmaceutical client's development and manufacturing needs, whether those needs are straightforward or complex. On a fee for service basis Halo will always remain committed to practical facilitation and implementation of non proprietary and client based solutions to scientific and technical challenges in the areas of pre-formulation, analytical method development, formulation, scale up, regulatory submission and commercial manufacturing. These approaches typically generate significant new wholly client owned IP.
With this new investment in, and association with, Altus Formulations, Halo takes a first step in offering to clients, when needed, an entire suite of proprietary scientific and technical solutions designed to solve intractable issues in such areas as drug solubility, bioavailability, tamper and abuse deterrence, and precisely managed drug dosage delivery. These proprietary solutions cover a wide range of non-sterile and sterile dosage forms. One such area requiring solution is the currently much discussed question of the need for abuse resistance for narcotic analgesic and other frequently abused CNS drugs.
In commenting on the collaboration with Altus the CEO of Halo Pharma Clive Bennett said, "We are delighted to have this new association with Altus as it will allow Halo to provide novel proprietary solutions to clients with difficult formulation problems in addition to those already available public domain and client originated solutions that we have historically offered."
Damon Smith CEO of Altus Formulation remarked, "The Altus team is extremely excited to be collaborating with Halo Pharma with their track record of excellence in the contract development and manufacturing fields. By combining our strengths Altus and Halo offer a full range of development and delivery options that are ideally placed to meet the needs of the industry."
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.